(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.
Quince Therapeutics's earnings in 2026 is -$56,979,000.On average, 6 Wall Street analysts forecast QNCX's earnings for 2026 to be -$57,663,751, with the lowest QNCX earnings forecast at -$83,271,668, and the highest QNCX earnings forecast at -$41,510,551. On average, 5 Wall Street analysts forecast QNCX's earnings for 2027 to be -$59,551,354, with the lowest QNCX earnings forecast at -$89,329,814, and the highest QNCX earnings forecast at -$26,894,160.
In 2028, QNCX is forecast to generate -$3,123,732 in earnings, with the lowest earnings forecast at -$26,192,573 and the highest earnings forecast at $21,632,259.